Xvivo Perfusion: Moving the needle
Research Update
2019-10-25
08:25
Sales came in higher than we expected in Q3 and also beat the street expectation. We forecast sales of SEK 66.8 million and EBITDA of SEK 14.1 million Q4’19.
AN
Arvid Necander
Disclosures and disclaimers